Cybin Inc. (CYBN): Bathi resik saben saham sajrone 12 wulan pungkasan

Cybin Inc. relies on strategic fundraising and patent protection, yet regulatory barriers in the psychedelic sector create uncertainty. The 12-month earnings per share history visualizes the struggle between these factors, where the value of -3.90 expresses the metric level. Growth prospects are supported by the implementation of AI modules for neuroimaging analysis and the robotization of molecule screening.

Cybin Inc. is a clinical-stage developer with no commercial revenue, whose viability relies entirely on raising external capital. Negative operating cash flow dictates the calculation logic of the metric as the ratio of total net loss to the number of shares, which allows the annual net income per share to track the cash burn rate and the fundamental value of each security.